个人科研网厅 | | 帮助
高级检索
当前位置： 首页 > 详情页

Real-World Prevalence of PD-L1 Expression in Chinese Patients with Advanced or Metastatic NSCLC: Express II Study

| 认领 | 导出 |

文献详情

资源类型：
WOS体系：

收录情况： ◇ SCIE

作者：
Lin, D.[1] * ; Yang, X.[1] ; Jiang, L.[2] ; Wang, W.[2] ; Hou, Y.[3] ; Li, Y.[4] ; Jin, Y.[4] ; Fan, X.[5] ; Sun, W.[6] ; Yun, J.[7] ; Li, P.[7] ; Kuang, D.[8] ; Zhang, L.[9] ; Ni, J.[10] ; Mao, A.[11] ; Tang, W.[11] ; Liu, Z.[11] ; Wang, J.[11] ; Xiao, S.[11] ;
单位： [1]Beijing Canc Hosp, Beijing, Peoples R China [2]Sichuan Univ, West China Hosp, Chengdu, Peoples R China [3]Fudan Univ, Zhongshan Hosp, Shanghai, Peoples R China [4]Fudan Univ, Shanghai Med Coll, Dept Pathol, Shanghai, Peoples R China [5]Nanjing Drum Tower Hosp, Nanjing, Peoples R China [6]Zhejiang Canc Hosp, Hangzhou, Zhejiang, Peoples R China [7]Sun Yat Sen, Canc Hosp, Guangzhou, Peoples R China [8]Huazhong Univ Sci & Technol, Tongji Hosp, Tongji Med Coll, Shanghai, Peoples R China [9]Shanghai Pulm Hosp, Shanghai, Peoples R China [10]First Hosp Jilin Univ, Eastern Div, Changchun, Peoples R China [11]Bldg A,Headquarters Pk Phase 2,1582 Gumei Rd, Shanghai, Peoples R China
出处：
ISSN：

关键词： Non-small cell lung cancer programmed death-ligand 1 IHC

语种：
外文
被引次数：
WOS：
中科院(CAS)分区：
出版当年[2020]版：
大类 | 1 区 医学
小类 | 1 区 肿瘤学 1 区 呼吸系统
最新[2025]版：
大类 | 1 区 医学
小类 | 1 区 肿瘤学 1 区 呼吸系统
JCR分区：
出版当年[2019]版：
Q1 RESPIRATORY SYSTEM Q1 ONCOLOGY
最新[2023]版：
Q1 ONCOLOGY Q1 RESPIRATORY SYSTEM

影响因子： 最新[2023版] 最新五年平均 出版当年[2019版] 出版当年五年平均 出版前一年[2018版] 出版后一年[2020版]

第一作者：
第一作者单位： [1]Beijing Canc Hosp, Beijing, Peoples R China
推荐引用方式(GB/T 7714)：
Lin D.,Yang X.,Jiang L.,et al.Real-World Prevalence of PD-L1 Expression in Chinese Patients with Advanced or Metastatic NSCLC: Express II Study[J].JOURNAL OF THORACIC ONCOLOGY.2021,16(3):S410-S410.
APA：
Lin, D.,Yang, X.,Jiang, L.,Wang, W.,Hou, Y....&Xiao, S..(2021).Real-World Prevalence of PD-L1 Expression in Chinese Patients with Advanced or Metastatic NSCLC: Express II Study.JOURNAL OF THORACIC ONCOLOGY,16,(3)
MLA：
Lin, D.,et al."Real-World Prevalence of PD-L1 Expression in Chinese Patients with Advanced or Metastatic NSCLC: Express II Study".JOURNAL OF THORACIC ONCOLOGY 16..3(2021):S410-S410

相关文献

[1]A meta-analysis reveals prognostic role of programmed death ligand-1 in Asian patients with non-small cell lung cancer [2]Cadonilimab (AK104) Plus Chemotherapy as First-line Treatment in Non-squamous Non-Small Cell Lung Cancer (NSCLC) Patients With Programmed Cell Death Ligand 1 (PD-L1) Negative [3]A meta-analysis of the efficacy of programmed cell death 1/its ligand inhibitors plus cytotoxic T-lymphocyte-associated antigen 4 inhibitors in non-small cell lung cancer [4]PD-L1 Expression in Chinese Patients with Advanced Non-Small Cell Lung Cancer (NSCLC): A Multi-Center Retrospective Observational Study [5]Study of Pembrolizumab (MK-3475) Monotherapy Versus Sacituzumab Govitecan in Combination With Pembrolizumab for Participants With Metastatic Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥50% (MK-3475-D46) [6]Programmed cell death-1/programmed cell death ligand-1 checkpoint inhibitors: differences in mechanism of action [7]程序性死亡蛋白1/程序性死亡蛋白配体1在恶性胶质瘤中的研究进展 [8]Pilot Study on the Tumor Immune Microenvironment Between Non-Small Cell Lung Cancer (NSCLC) and Small Cell Lung Cancer (SCLC) [9]HIF-1α和LOX在非小细胞癌中的表达及其临床意义 [10]Emerging role of deubiquitination modifications of programmed death-ligand 1 in cancer immunotherapy

资源点击量：426 今日访问量：0 总访问量：408 更新日期：2025-04-01 建议使用谷歌、火狐浏览器 常见问题

版权所有：重庆聚合科技有限公司 渝ICP备12007440号-3 地址：重庆市两江新区泰山大道西段8号坤恩国际商务中心16层（401121）